AttendMe Owl Logo
AttendMe
Sign In
All Pathways
RadiologyDiagnostic

Gadolinium NSF Risk Assessment (ACR 2024)

Gadolinium NSF Risk Assessment (ACR 2024): Gadolinium Contrast MRI Ordered → NSF Background → Check eGFR → eGFR Level → eGFR ≥30 mL/min/1.73m².

Pathway Overview

11 steps

Algorithm Steps

11 total

  1. 01Start

    Gadolinium Contrast MRI Ordered

    Assess NSF risk before administration

  2. 02Action

    NSF Background

    Understanding the risk

    • NEPHROGENIC SYSTEMIC FIBROSIS:
    • - Fibrosing disorder of skin/organs
    • - Associated with GBCA in renal impairment
    • - Can be disabling or fatal
    • - No effective treatment
    • - Onset: Days to months after exposure
    • SYMPTOMS:
    • - Skin thickening/hardening
    • - Joint contractures
    • - Organ fibrosis (rare)
    • PREVENTION IS KEY
  3. 03Action

    Check eGFR

    Kidney function assessment

    • WHEN TO CHECK eGFR:
    • - All patients before Group I agents
    • - Patients with known renal disease
    • - Diabetes, hypertension, age >60
    • - History of kidney disease
    • - Single kidney, transplant
    • ACCEPTABLE TIMING:
    • - Within 6 weeks for stable patients
    • - Same day for unstable/inpatient
  4. 04Decision

    eGFR Level

    Risk stratification

  5. 05Action

    eGFR ≥30 mL/min/1.73m²

    Standard risk

    • Any GBCA may be used
    • Group I, II, or III agents OK
    • Standard precautions
    • No special restrictions
  6. 06Action

    ACR GBCA Risk Groups

    Agent classification

    • GROUP I (High Risk - NSF associated):
    • - Gadodiamide (Omniscan)
    • - Gadopentetate dimeglumine (Magnevist)
    • - Gadoversetamide (OptiMARK)
    • GROUP II (Low Risk):
    • - Gadobenate dimeglumine (MultiHance)
    • - Gadobutrol (Gadavist)
    • - Gadoterate meglumine (Dotarem)
    • - Gadoteridol (ProHance)
    • GROUP III (Insufficient Data):
    • - Gadoxetate disodium (Eovist)
    • - Gadopiclenol (Elucirem)
  7. 07Action

    Consider Alternatives

    When MRI contrast risky

    • NON-CONTRAST MRI:
    • - May answer clinical question
    • - Time-of-flight angiography
    • - Diffusion-weighted imaging
    • ALTERNATIVE MODALITIES:
    • - CT with iodinated contrast
    • - Ultrasound
    • - Nuclear medicine
    • RISK-BENEFIT DISCUSSION:
    • - Document discussion with patient
    • - Informed consent if proceeding
  8. 08Action

    Acute Kidney Injury

    Special situation

    • AKI: Potentially higher risk
    • eGFR may not reflect true function
    • If GBCA needed:
    • - Use Group II agent
    • - Lowest dose possible
    • - Document medical necessity
    • - Consider nephrology input
    • Avoid if possible until AKI resolved
  9. 09Outcome

    Summary

    Key points

    • NSF is rare with Group II agents
    • Group I agents: Avoid if eGFR <30
    • Prevention is only treatment
    • Document risk assessment
    • Consider non-contrast alternatives
    • NSF incidence has dropped dramatically with risk screening
  10. 10Action

    eGFR <30 mL/min/1.73m² (not on dialysis)

    Increased risk - agent selection critical

    • GROUP I AGENTS: CONTRAINDICATED
    • - Gadodiamide (Omniscan)
    • - Gadopentetate (Magnevist)
    • - Gadoversetamide (OptiMARK)
    • GROUP II AGENTS: USE WITH CAUTION
    • - Gadobenate (MultiHance)
    • - Gadobutrol (Gadavist)
    • - Gadoterate (Dotarem)
    • - Gadoteridol (ProHance)
    • Use lowest effective dose
  11. Path rejoins step 06Shared downstream outcome
  12. 11Action

    On Dialysis (HD or PD)

    Special considerations

    • GROUP I: CONTRAINDICATED
    • GROUP II: May be used with caution
    • POST-MRI DIALYSIS:
    • - Hemodialysis: Consider within 3h
    • - Does NOT prevent NSF
    • - May reduce risk (unproven)
    • - Extra session after MRI reasonable
    • PD: Multiple rapid exchanges (limited data)
  13. Path rejoins step 06Shared downstream outcome

Guideline Source

ACR Manual on Contrast Media 2024 - Nephrogenic Systemic Fibrosis

DOI: N/A

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • NSF diagnosis is clinical/pathologic
  • No specific treatment exists
  • Risk varies by agent group
  • Dialysis timing uncertain benefit

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Related Radiology Pathways

Acute Abdomen Imaging Selection (ACR)

Diagnostic

Acute Stroke Imaging Protocol (AHA/ASA)

Diagnostic

Contrast Allergy Management (ACR 2021)

Management

Contrast Extravasation Management (ACR 2024)

Emergency

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

Body Mass Index

Weight classification based on height and weight

Open page

Compare

AttendMe.ai vs UpToDate

See how this pathway workflow compares against UpToDate.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Gadolinium NSF Risk Assessment (ACR 2024)?

The Gadolinium NSF Risk Assessment (ACR 2024) is a diagnostic clinical algorithm for Radiology. It provides a structured decision tree to guide clinical decision-making, based on ACR Manual on Contrast Media 2024 - Nephrogenic Systemic Fibrosis.

What guideline is the Gadolinium NSF Risk Assessment (ACR 2024) based on?

This algorithm is based on ACR Manual on Contrast Media 2024 - Nephrogenic Systemic Fibrosis (DOI: N/A).

What are the limitations of the Gadolinium NSF Risk Assessment (ACR 2024)?

Known limitations include: NSF diagnosis is clinical/pathologic; No specific treatment exists; Risk varies by agent group; Dialysis timing uncertain benefit. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Gadolinium NSF Risk Assessment (ACR 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free